VivoSeq
Cardiovascular

Ischemia Reperfusion Injury

26

Pipeline Programs↗

1

Active Trials↗

20

Companies Involved↗

Ischemia Reperfusion Injury is an emerging landscape with 26 programs across 20 companies. The most active players are Roche, Neurim Pharmaceuticals Ltd., Immunex. 15 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

6/100

Mech. Concentration

10/100

Completion Rate

67/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 2N

Neurim Pharmaceuticals Ltd.

1 program

Phase 2I

Immunex

1 program

Phase 2J

Jiangsu Carephar Pharmaceutical Co., Ltd.

1 program

Phase 2V

Veloxis Pharmaceuticals

1 program

Phase 3Bayer logo

Bayer

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

25 of 28 classified programs — the dominant modality here.

11%ALL OTHERSMonoclonal antibody27%Protein / enzyme14%

Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 91% of 32 pipeline programs.

Analysis

Trial Status

7

clinical trials

Completed4 · 57%
Withdrawn1 · 14%
Terminated1 · 14%
Recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Randomized, Single-blind, Multi-center, Placebo-controlled, Phase 2a Clinical Trial of BX-001N to Prevent From Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE)
Recruiting·BBilix Co.,Ltd.·Phase 2·NCT07164833·50 enrolled
Role of Sympathetic Activation in Ischemia Reperfusion Injury
Completed·RRoyal Perth Hospital·Phase 4·NCT04479813·46 enrolled
Sevoflurane Protective Effect on Ischemia Reperfusion Injury in Microvascular Surgery
Completed·RRegina Elena Cancer Institute·N/A·NCT01972230·128 enrolled
The Effect of EPLerenone on Ischemia Reperfusion Injury in Human myoCARDium
Completed·RRadboud University Medical Center·N/A·NCT02118753·24 enrolled
Antinociceptive Modalities on Ischemia Reperfusion Injury
Completed·NNational Taiwan University Hospital·N/A·NCT01932918·142 enrolled
TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion
Terminated·LLudwig-Maximilians - University of Munich·Phase 2/3·NCT01564095·25 enrolled
Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation
Withdrawn·GGeorgetown University·Phase 4·NCT01149993

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)